Lab to Lives

A simple question started this show: How do we medicine from the lab to making a difference in people's lives as quickly as possible? The answers are complex. Actual solutions are hard to come by. We want to distill ideas until we see actual impact in the industry. Our three hosts all have backgrounds in life sciences and in improv comedy. Together, with their guests, they're on a mission to have conversations that can have an impact. And have some fun along the way.

Lab to Lives is a science podcast hosted by Ivanna Rosendal, with 95 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Ivanna Rosendal hosts Lab to Lives, a science show with 95 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #6

  Enabling Clinical Trial Technology that Cuts Risk and Speeds Patient Access

  Aug 26, 202645 minS8

  Send us Fan Mail Clinical trials are meant to generate evidence, not paperwork, but too many studies still depend on spreadsheets, duplicate data entry and unconnected systems. This episode we are joined by Karen Maduschke, a clinical trial technology leader with over 20 years of experience, from building one of the first interactive e-consent products to scaling trial tech through acquisition and entry into a global CRO environment. Together we explore one of most pressing challenges in Clinical Trials: moving faster without sacrificing integrity. Karen breaks down why “speed” is really a workflow problem, how poor integration creates site burden and error risk, and where new technologies and automation can genuinely help. We also talk about what must come alongside that shift: validation, information security, patient privacy and clear governance to protect patients and control risk. The episode also touches on practical tips if you are a founder selling into pharma R&D. We map the different corporate players you need to get on board and to buy into your product, not simply your technology - from clinical operations and procurement, to QA, legal, IT and information security. We also explain why pharma does not buy shiny tech, but reduced risk and faster delivery. FInally we finish with our ever fun game show round focused this episode on "How couch was this trial?" exploring the extent to which decentralisation in trials is becoming a reality? Subscribe for more, share this with a founder or trial leader who needs it, and leave us a review with your biggest barrier to a faster, cleaner transition from Labs to Lives. Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ Support the show ________ Reach out to Ivanna Rosendal Join the conversation on our LinkedIn page Visit www.labtolives.com Hosts Alexander Booth aka the MedTech Guy Dimitri Borisevich aka the start-up Guy Ivanna Rosendal aka the R&D pharma Gal

  ListenShow Notes
• 

  Episode #5

  The Emperor’s Naked And The Trial’s Still On w/ Dr. Grant Coren

  Jul 7, 20261h 6mS8

  Send us Fan Mail “Patients first” sounds simple until you follow the incentives. We’re joined by Dr Grant Coren, a genetics-trained PhD who moved from cancer research into decades of recruiting talent across the pharmaceutical industry and biotech. Together, we ask the uncomfortable question that sits under mission statements and glossy brand values: do pharma organisations truly value patients over profit, or do we build systems where profit is the only thing we reliably measure and reward? We explore why communication breaks down, from jargon-heavy emails to patient-facing information that is technically compliant but hard to understand. From there, the conversation widens into how risk aversion accumulates through thousands of “safe” micro decisions, why Big Pharma often outsources early discovery risk to biotech, and what happens when acquired biotechs get assimilated into slower, more process-heavy cultures. We also talk leadership and psychological safety: brilliant people can want change and still feel unable to back a decision if being wrong is punished. Technology and data get a hard look too. AI in pharma is attracting billions, but adoption is often blocked by culture, incentives, and a habit of hiding behind regulation rather than engaging regulators to modernise clinical trials. We then zoom out to funding realities and industrial policy, including whether state involvement and public-private partnerships could help fix market failures, especially as cell and gene therapies challenge old pricing and reimbursement models. If you care about patient-centric drug development, clinical trials, biotech innovation, and the future of healthcare incentives, you’ll find plenty to argue with and plenty to take back to your team. Subscribe, share this with a colleague, and leave a review with your take: what would you change first to put patients ahead of profit? Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ Support the show ________ Reach out to Ivanna Rosendal Join the conversation on our LinkedIn page Visit www.labtolives.com Hosts Alexander Booth aka the MedTech Guy Dimitri Borisevich aka the start-up Guy Ivanna Rosendal aka the R&D pharma Gal

  ListenShow Notes
• 

  Episode #4

  What If The Real Blocker Is Coordination Not Data w/ Anastasia Christianson

  Jun 9, 202652 minS8

  <p>Send us Fan Mail</p><p>AI is everywhere in pharma right now, yet drug development still feels slow, fragmented, and full of avoidable rework. We sit down with Anastasia Christianson, former SVP and Global Head of AI Data and Analytics at Pfizer and now Managing Principal at EPAM Life Science Consulting, to get specific about what actually blocks progress in clinical trials and what AI can realistically change.<br/><br/>We dig into the uncomfortable pattern behind many “successful” AI deployments: a model fixes one bottleneck, then the system simply jams up somewhere else. Anastasia makes the case for...

  ListenShow Notes
• 

  Episode #3

  Electrifying the Factory: Agentic AI For Faster Clinical Trials with Pamela Tenaerts

  May 13, 202649 minS8

  <p>Send us Fan Mail</p><p>The clinical trial system is starting to look like a motorway at a standstill: more and more drugs are lining up, but the lanes ahead are already full. We sit down with Pamela Tenart to unpack why the industry may have reached the limit of human-only clinical development, and why “adding more people” is no longer a realistic plan when experienced CRAs, site co-ordinators and trial operators are already stretched thin.<br/><br/>From there, we get practical about what agentic AI could change inside clinical trial operations. We talk about AI agents that...

  ListenShow Notes
• 

  Episode #2

  Why Big Pharma Feels Like A Financial Institution & Don't Pee on Medical Gloves with Anish Shindore

  Apr 15, 20261h 9mS8

  <p>Send us Fan Mail</p><p>A medicine can be proven safe and effective, approved by regulators, and still fail the one test that matters: actually reaching patients in the real world. We sit down with Anish, a deep commercial thinker, to unpack what pharmaceutical commercialisation really is when you strip away the slogans and look at incentives, bottlenecks, and human behaviour. <br/><br/>We start with our five value streams model of the pharmaceutical industry and use it to explore a provocative idea: modern big pharma often functions like a financial institution with extraordinary risk tolerance and time h...

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.